Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 2, 2026Journal of BiophotonicsOpen Access

Autofluorescence Imaging and Methylene Blue‐Mediated Photodynamic Therapy for Early Detection and Management of Subclinical Actinic Cheilitis

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJuliana Cristina Oliverio de AraújoOJOg Fray JuniorHPHermano Camelo Paiva

Discussion

Loading...

Member takes

Overview

Clinical study reveals autofluorescence imaging and photodynamic therapy effectively detect and treat actinic cheilitis, highlighting a viable noninvasive approach for high-risk oral lesions.

Key Points

  • To evaluate optical autofluorescence imaging for the early detection of actinic cheilitis and for monitoring tissue response following methylene blue-mediated photodynamic therapy.
  • Screened 25 individuals using a handheld autofluorescence imaging device (405 ± 20 nm), performing diagnostic biopsies on areas exhibiting altered fluorescence.
  • Treated patients with confirmed actinic cheilitis with five sessions of photodynamic therapy (topical 1% methylene blue, 660 nm, 100 mW, 120 s/point).
  • Quantified lip autofluorescence grayscale intensity at baseline and at 30-day post-treatment follow-up (N=17 completed follow-up).
  • Biopsy confirmed actinic cheilitis in 19 of 25 screened individuals, with affected areas demonstrating higher fluorescence intensity than healthy lip tissue.
  • Mean grayscale intensity and variability decreased significantly 30 days after photodynamic therapy, demonstrating therapeutic tissue response.
  • Patients who smoked exhibited a smaller overall reduction in fluorescence intensity following photodynamic therapy compared to non-smokers.

Cite This Study

Araújo et al. (2026) studied this question.

synapsesocial.com/papers/6a97e29ec562ede874ec6d39https://doi.org/10.1002/jbio.70346
View Full Paper
Ask AI
Bookmark
Share